Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents

Pediatrics

Volumn 117, Issue 4, 2006, Pages 1084-1093

  Pichichero, Michael E ^a   Blatter, Mark M ^b   Kennedy, William A ^c   Hedrick, James ^d   Descamps, Dominique ^e   Friedland, Leonard R ^f  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b Primary Physicians Research   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Kentucky Pediatric Research Institute   (United States)

^e GSK   (Belgium)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Adolescents; Diphtheria; Pertussis; Tetanus; Vaccine

Indexed keywords

DIPHTHERIA TOXOID; HEMAGGLUTININ; PERTACTIN; PERTUSSIS VACCINE; TETANUS TOXOID; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPHTHERIA; DRUG SAFETY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PERTUSSIS; PRIORITY JOURNAL; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SYMPTOMATOLOGY; TETANUS; ADOLESCENT; BIOSYNTHESIS; BORDETELLA PERTUSSIS; CHILD; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; IMMUNOLOGY;

ADOLESCENT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS VACCINE; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNIZATION, SECONDARY; TETANUS TOXOID; VACCINES, COMBINED;

EID: 33646367171     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2005-1759     Document Type: Article

References (37)

1. Centers for Disease Control and Prevention. Pertussis: United States, 1997-2000. MMWR Morb Mortal Wkly Rep. 2002;51:73-76
2. Centers for Disease Control and Prevention. Pertussis Surveillance Report: 8/12/05 (final data). Atlanta, GA: Bacterial Vaccine Preventable Diseases Branch, National Immunization Program, Centers for Disease Control and Prevention; 2005
3. Güriş D, Strebel PM, Bardenheier B, et al. Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis. 1999;28:1230-1237
4. Yih WK, Lett SM, des Vignes FN, Garrison KM, Sipe PL, Marchant CD. The increasing incidence of pertussis in Massachusetts adolescents and adults, 1989-1998. J Infect Dis. 2000;182:1409-1416
5. Sotir MJ, Cappazzo DL, Schmidt CE, et al. A resource and labor intensive county-wide outbreak of pertussis, Wisconsin, 2003: high impact on the adolescent population (abstract). Presented at: the 39th National Immunization Conference; March 21-24, 2005; Washington, DC
6. Strebel P, Nordin J, Edwards K, et al. Population-based incidence of pertussis among adolescents and adults, Minnesota, 1995-1996. J Infect Dis. 2001;183:1353-1359
7. Ward JI, Cherry JD, Chang S-J, et al, for the APERT Study Group. Efficacy of acellular pertussis vaccine among adolescents and adults. N Engl J Med. 2005;353:1555-1563
8. Wirsing von König CH, Postels-Multani S, Bogaerts H, et al. Factors influencing the spread of pertussis in households. Eur J Pediatr. 1998;157:391-394
9. Aoyama T, Harashima M, Nishimura K, Saito Y. Outbreak of pertussis in highly immunized adolescents and its secondary spread to their families. Acta Paediatr Jpn. 1995;37:321-324
10. Senzilet LD, Halperin SA, Spika JS, Alagaratnam M, Morris A, Smith B, and the Sentinel Health Unit Surveillance System Pertussis Working Group. Pertussis is a frequent cause of prolonged cough illness in adults and adolescents. Clin Infect Dis. 2001;32:1691-1697
11. Hewlett EL, Edwards KM. Pertussis: not just for kids. N Engl J Med. 2005;352:1215-1222
12. Lee GM, Lett S, Schauer S, et al. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis. 2004;39:1572-1580
13. Lee LH, Pichichero ME. Costs of illness due to Bordetella pertussis in families. Arch Fam Med. 2000;9:989-996
14. Pichichero ME, Treanor J. Economic impact of pertussis. Arch Pediatr Adolesc Med. 1997;151:35-40
15. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA. Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J. 2005;24:S75-S82
16. Purdy KW, Hay JW, Botteman MF, Ward JI. Evaluation strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004;39:20-28
17. Wharton M. Prevention of pertussis among adolescents by vaccination: taking action on what we know and acknowledging what we do not know [editorial]. Clin Infect Dis. 2004;39:29-30
18. Lee GM, LeBaron C, Murphy TV, Lett S, Schauer S, Lieu TA. Pertussis in adolescents and adults: should we vaccinate? Pediatrics. 2005;115:1675-1684
19. Forsyth KD, Campins-Marti M, Caro J, et al, for the Global Pertussis Initiative. New pertussis vaccination strategies beyond infancy: recommendations by the Global Pertussis Initiative. Clin Infect Dis. 2004;39:1802-1809
20. Greco D, Salmaso S, Mastrantonio P, et al, and the Progetto Pertosse Working Group. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med. 1996;334:341-348
21. Schmitt HJ, Wirsing von König CH, Neiss A, et al. Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA. 1996;275:37-41
22. Wassilak SGF, Roper MH, Murphy TV, Orenstein WA. Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:745-781
23. Wharton M, Vitek CR. Diphtheria toxoid. In: Plotkin SA, Orenstein WA, Offit PA, eds. Vaccines. 4th ed. Philadelphia, PA: Saunders; 2004:211-228
24. Food and Drug Administration Center for Biologics Evaluation and Research. Vaccines and Related Biological Products Advisory Committee (day one). 1997. Available at: www.fda.gov/ohrms/dockets/ac/97/transcpt/3300t1. pdf. Accessed April 5, 2005
25. Schmitt HJ, Schuind A, Knuf M, et al. Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants. J Pediatr. 1996;129:695-701
26. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis. 2003;14:196-198
27. Woo EJ, Burwen DR, Gatumu SNM, Ball R, and the Vaccine Adverse Event Reporting System (VAERS) Working Group. Extensive limb swelling after immunization: reports to the vaccine adverse event reporting system. Clin Infect Dis. 2003;37:351-358
28. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics. 1997;100:772-786
29. Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on Immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAP). MMWR Recomm Rep. 2002;51(RR-2):1-35
30. Centers for Disease Control and Prevention. Diphtheria, tetanus, and pertussis: recommendations for vaccine use and other preventive measures. Recommendations of the immunization practices advisory committee (ACIP). MMWR Recomm Rep. 1991;40(RR-10):1-28
31. Salmaso S, Mastrantonio P, Tozzi AE, et al, and the Stage III Working Group. Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience. Pediatrics. 2001;108(5). Available at: www.pediatrics.org/cgi/content/ full/108/5/e81
32. McIntyre PB, Turnbull FM, Egan A-M, Burgess MA, Wolter JM, Schuerman LM. High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine. Vaccine. 2004;23:380-385
33. Edelman KJ, He Q, Makinen JP, et al. Pertussis-specific cell-mediated and humoral immunity in adolescents 3 years after booster immunization with acellular pertussis vaccine. Clin Infect Dis. 2004;39:179-185
34. Centers for Disease Control and Prevention. Recommended childhood and adolescent immunization schedule: United States, 2005. MMWR Morb Mortal Wkly Rep. 2005;53:Q1-Q3
35. Kandola K, Lea A, Santos M. Pertussis rates in Northwest Territories after introducing adult formulation acellular vaccine [abstract]. Can J Infect Dis Med Microbiol. 2004;15:351.
36. Pichichero ME, Rennels MB, Edwards KM, et al. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults. JAMA. 2005;293:3003-3011
37. Advisory Committee on Immunization Practices. ACIP recommends adolescent vaccination for tetanus, diphtheria and pertussis vaccine. Available at: www.cdc.gov/nip/pr/pr_tdap_jun2005. htm. Accessed July 5, 2005